Patents Assigned to AstraZeneca
  • NOVEL ADENINE COMPOUND
    Publication number: 20090192153
    Abstract: An adenine compound or its pharmaceutically acceptable salt as a medicament as shown following formula (1): wherein R1 is optionally substituted alkyl group, etc., X is oxygen atom, etc., A is 4 to 8 membered optionally substituted saturated or unsaturated heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom and 0 to 1 sulfur atom, L1 and L2 are independently straight or branched chain alkylene, or a single bond, R2 is optionally substituted alkyl group, etc.
    Type: Application
    Filed: September 21, 2006
    Publication date: July 30, 2009
    Applicants: Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag A corporation of Sweden
    Inventors: Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura, Ayumu Kurimoto, Yoshiaki Isobe, Haruhisa Ogita, Ian Millichip, Thomas Mcinally, Roger Bonnert
  • 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor
    Patent number: 7566727
    Abstract: This invention encompasses nicotinic acetylcholine receptor reactive compounds in accord with formula (I) Wherein: D represents O; E represents CH2, NH, O or S; n is 1 or 2 and stereoisomers, enantiomers, in vivo-hydrolysable precursors and pharmaceutically-acceptable salts of such compounds, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: July 28, 2009
    Assignee: AstraZeneca AB
    Inventors: Marc Chapdelaine, Keith J. Herzog
  • Crystalline forms
    Patent number: 7566788
    Abstract: A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a citric acid salt, a methanesulphonic acid salt, or a p-toluenesulphonic acid salt of said compound.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: July 28, 2009
    Assignee: AstraZeneca AB
    Inventor: Martin Bohlin
  • Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative
    Publication number: 20090186890
    Abstract: A pharmaceutical composition comprising 4-(3?-chloro-4?-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from solution.
    Type: Application
    Filed: September 19, 2008
    Publication date: July 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Paul Richard Gellert, Marcel De Matas, Michael Davis Parker
  • Therapeutic Agents - 802
    Publication number: 20090186870
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: October 9, 2008
    Publication date: July 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood
  • Pyridine Analogues II
    Publication number: 20090186876
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) [Chemical formula should be inserted here. Please see paper copy] Formula (I) to processes for preparing such compounds, to their utility in medicine in general and especially as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: June 26, 2007
    Publication date: July 23, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Fredrik Zetterberg
  • Synergistic Pharmaceutical Composition
    Publication number: 20090181980
    Abstract: A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor.
    Type: Application
    Filed: May 9, 2007
    Publication date: July 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Meenakshi Balganesh, Santosh Nandan
  • Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides
    Publication number: 20090181968
    Abstract: The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A1, A2, R1, R2, R3, R4, and R5 and n are as defined in the specification. The compounds of formula (I) are useful in therapy.
    Type: Application
    Filed: November 22, 2006
    Publication date: July 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kosrat Amin, Johan Broddefalk, Yantao Chen, Karolina Nilsson, Claire Milburn, Helene Desfosses, Ziping Liu, Maxime Tremblay, Christopher Walpole, Zhong-yong Wei, Hua Yang
  • Salts of omeprazole and esomeprazole II
    Patent number: 7560472
    Abstract: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: July 14, 2009
    Assignee: AstraZeneca AB
    Inventors: Mikael Dahlström, Bo Lindqvist
  • Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1
    Publication number: 20090176851
    Abstract: The present invention relates to a new use of spiro-hydantoin derivatives of formula (I), or salts, solvates or solvated salts thereof, as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.
    Type: Application
    Filed: February 6, 2007
    Publication date: July 9, 2009
    Applicant: AstraZeneca AB
    Inventors: Lucy Horoszok, Carmen Leung, Miroslaw Tomaszewski, Christopher Walpole
  • Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
    Publication number: 20090176850
    Abstract: This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 9, 2009
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Jeffrey Albert, James Arnold, Gianni Chessari, Miles Stuart Congreve, Phil Edwards, Christopher Murray, Sahil Patel
  • Process for the preparation of alkyl phosphinates
    Patent number: 7557234
    Abstract: The invention relates to a new process for the production of alkyl dialkoxyalkylphosphinates. A hypophosphite salt is used in the process.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: July 7, 2009
    Assignee: AstraZeneca AB
    Inventors: Maths Nilsson, Mats Thelin, Johanna Wachtmeister
  • QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY
    Publication number: 20090170849
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: April 4, 2007
    Publication date: July 2, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • Thiophene carboxamides as inhibitors of the enzyme IKK-2
    Patent number: 7553868
    Abstract: The invention relates to thiophene carboxamides of formula (I) wherein Ar, R1, R2, R3, R4, R5, m and n are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: June 30, 2009
    Assignee: AstraZeneca AB
    Inventors: Andrew David Morley, Jeffrey Philip Poyser
  • Novel Protein Kinase B Inhibitors - 060
    Publication number: 20090163524
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Application
    Filed: October 10, 2008
    Publication date: June 25, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY
    Publication number: 20090163525
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: April 4, 2007
    Publication date: June 25, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian A. Aquila, Paul Lyne, Timothy Pontz
  • Bis-(Sulfonylamino) Derivatives in Therapy 205
    Publication number: 20090163586
    Abstract: The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: December 17, 2008
    Publication date: June 25, 2009
    Applicant: AstraZeneca AB
    Inventors: Johan Bylund, Maria E. Ek, Ylva Gravenfors, Jorg Holenz, Alexander Minidis, Gunnar Nordvall, Daniel Sohn, Karl S.A. Vallin, Jenny Viklund, Stefan Von Berg
  • Compounds, compositions containing them, preparation thereof and uses thereof I
    Patent number: 7550495
    Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: June 23, 2009
    Assignee: AstraZeneca AB
    Inventors: Daniel Pagé, Ziping Liu, Maxime Tremblay, Christopher Walpole, Hua Yang
  • Novel Use of a Nicotinic Receptor Agonist 156
    Publication number: 20090156625
    Abstract: The invention relates to a novel method of treatment or prophylaxis of osteoarthritis, which comprises administering to a patient in need thereof a therapeutically effective amount of an alpha 7 nicotinic AcetylCholine receptor agonist of Formula (I), or a pharmaceutically acceptable salt thereof:
    Type: Application
    Filed: November 21, 2008
    Publication date: June 18, 2009
    Applicant: AstraZeneca AB
    Inventors: Sarah Maria Valentine Brockbank, Maurice Ronald Charles Needham, Peter Newham, Timothy Martin Piser, Jeffrey Scott Smith
  • Process for the preparation of -(4-piperidinyl)--ethyl-phenylacetamides from -Boc-4-oxopiperidine
    Patent number: 7547789
    Abstract: The present invention concerns a process for the preparation of an N-(4-piperidinyl)-N-ethyl-phenylacetamide of formula (I); wherein R1 and R2 are independently selected from the group comprising: hydrogen, halogen, C1-4 alkyl, C1-4alkoxy, cyano and S(O)2(C1-4 alkyl).
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: June 16, 2009
    Assignee: Astrazeneca AB
    Inventors: Emma Anderson, John Pavey